%0 Journal Article
%T The markers predicting response to Hepatitis C virus treatment and evaluation of treatment responses
%A £¿zg¨¹r G¨¹nal
%A H¨¹seyin £¿ener Barut
%A ¨¹nal Erkorkmaz
%J Journal of Microbiology and Infectious Diseases
%D 2012
%I Association of Health Investigations
%X Objectives: Currently pegylated interferon alpha (peg-IFN) and ribavirin treatment is recommended for chronic hepatitis Ctreatment. The aim of treatment is to provide sustained viral response (SVR).Material and methods: A total of 125 patients, who have been treated for chronic hepatitis C diagnosis and are followed upuntil 6 months after treatment, were enrolled into the study. Markers, which have indicated treatment response against hepatitisC virus treatment, treatment responses according to peg-IFN¦Á type used, and experienced side effects in patients havebeen compared.Results: Of patients, 103 were (82.4%) female and 22 were (17.6%) male and mean of age was 54.74¡À7.93 years. Markersindicating SVR in our study were calculated as rapid viral response (RVR) (p<0.001); early viral response (EVR) (p<0.001); highbaseline thrombocyte (x103 / ¦Ìl) value (240,93 ¡À 75,61) (p<0.004); baseline total bilirubin level (0.55¡À0.19) (p<0.001) and hepaticfibrosis stage (according to Knodell or modified ISHAK staging >2) (p<0.034). Predictive parameters for EVR in our studywere defined as absence of diabetes in patients, high baseline lymphocyte numbers (2024.74¡À625.93) and high baseline cholesterollevel (in EVR positive patients 180.47¡À32.77 mg/dl; in EVR negatives 152.00¡À24.56). There was no statistical differencebetween peg-IFN type in patients and RVR, EVR and SVR. Also there was no statistical difference in hematological side effects(neutropenia, anemia, and thrombocytopenia) in both treatment groups.Conclusions: As the efficacy of treatment against HCV is defined, predictive markers for the treatment response are becomingmore significant. Therefore, it is concluded that these factors should also be considered in patient treatment plans. J MicrobiolInfect Dis 2012; 2(3): 100-108Key words: Treatment of Hepatitis C, Sustained Viral Response, Markers of Treatment
%K Treatment of Hepatitis C
%K Sustained Viral Response
%K Markers of Treatment
%U http://www.jcmid.org/upload/sayi/9/JMID-00605.pdf